Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 30 of 1,261
  1. US 12358928

    Compounds, compositions and methods

    DENALI THERAPEUTICS INC. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  2. US 12358968

    Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer

    Providence Health & Services—Oregon · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  3. US 12358952

    Compositions and methods of synthesizing shape shifting cyclic peptides (Sscp) and their use in the identification of novel therapeutic compounds

    The Regents of the University of Colorado · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  4. US 12357687

    Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same

    EnGeneIC Molecular Delivery Pty Ltd · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  5. US 12357598

    Treatment of neurodevelopmental disorders

    The Regents of the University of California · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  6. US 12358863

    Nitrogen-containing derivative of substituted phenol hydroxy acid ester, and preparation and use thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  7. US 2025222125

    Anti-FGFR2b Antibodies, Conjugates and Methods of Use

    BEIGENE LTD [KY] · Granted Jul 10, 2025 · Expires Jul 5, 2045

    granted
  8. WO 2025146482

    FINÉRÉNONE DESTINÉE À ÊTRE UTILISÉE DANS UN PROCÉDÉ DE PRÉVENTION OU DE TRAITEMENT D'UNE INSUFFISANCE CARDIAQUE CHEZ UN PATIENT RECEVANT UN INHIBITEUR DE CYP3A4 OU UN INDUCTEUR DE CYP3A4

    BAYER AG [DE] · Granted Jul 10, 2025 · Expires Jul 5, 2045

    granted
  9. WO 2025147499

    LUTIKIZUMAB DESTINÉ À ÊTRE UTILISÉ DANS UN TRAITEMENT DE L'HIDRADÉNITE SUPPURÉE

    ABBVIE INC [US] · Granted Jul 10, 2025 · Expires Jul 5, 2045

    granted
  10. WO 2025146444

    DAROLUTAMIDE EN COMBINAISON AVEC DES INHIBITEURS DE BRAF ET DE MEK POUR LE TRAITEMENT D'UN MÉLANOME

    BAYER AG [DE] · Granted Jul 10, 2025 · Expires Jul 5, 2045

    granted
  11. US 12351590

    Pyrrolopyrimidine compound and use thereof

    Medshine Discovery Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  12. US 12351574

    Selective ligands for modulation of GIRK channels

    Northwestern University · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  13. US 12350374

    Fabrication of protein-encapsulating microgels

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  14. US 12351579

    Compounds and uses thereof

    FOGHORN THERAPEUTICS INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  15. US 12350383

    Cationic lipids containing silicon

    ARBUTUS BIOPHARMA CORPORATION · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  16. US 12351609

    Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload

    The Board of Regents of the University of Texas System · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  17. US 12350338

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  18. US 12350343

    Bicyclic peptide ligands specific for MT1-MMP

    BicycleTx Limited · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  19. US 12350242

    Binge behavior regulators

    CLEARMIND MEDICINE INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  20. US 12350322

    Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation

    United Biomedical, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  21. US 12351649

    Antibodies to oxidation-specific epitopes

    The Regents of the University of California · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  22. US 12350245

    Stable oral suspensions of baclofen

    ANI Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  23. US 12350253

    Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  24. US 12350258

    Compositions and methods for treatment of skin-related diseases and promoting dermatological health

    Script Essentials, LLC · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.